Venetoclax Plus Obinutuzumab May Improve PFS, Not OS in Chronic Lymphocytic Leukemia
Patients with previously untreated CLL had superior PFS with fixed duration venetoclax plus obinutuzumab, with or without ibrutinib.
Chronic Lymphocytic Leukemia News
CHRONIC LYMPHOCYTIC LEUKEMIA ADVISOR
Chronic Lymphocytic Leukemia News
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
Eponyms in Oncology: Bence-Jones Protein
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of the Bence-Jones protein.
Vaccine-Induced Responses to Omicron, Delta Impaired in Non-Hodgkin Lymphoma Patients
Of the NHL patients with neutralizing antibodies against the WA1/2020 SARS-CoV-2 strain, 70% had antibodies against the delta variant, and 33% had antibodies against the omicron variant.
Ukoniq Taken Off the Market; Pending Applications for CLL, SLL Withdrawn
TG Therapeutics has decided to take Ukoniq (umbralisib) off the market and withdraw pending applications for the drug.
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Venetoclax Plus Dose-Adjusted R-EPOCH Yields Durable Responses in Richter Syndrome
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Drugs in Phase 1 Trials Becoming More Effective, No Less Fatal
Response rates improved from 2000 to 2019, but the rate of treatment-related fatal toxicities remained stable.
FDA: Safety Concerns With Lymphoma Drug Ukoniq
An initial review of data from the phase 3 UNITY trial in CLL patients showed the combination of Ukoniq and ublituximab was associated with increased risk of death compared with the control arm.
Overall, Night Shift Work Not Tied to Higher Lymphoma Risk
Night shift work may increase the risk of developing chronic lymphocytic leukemia but not other types of lymphoma.
Prognostic Index May ID CLL Patients Who Will Not Need Treatment
A novel prognostic index can identify patients with chronic lymphocytic leukemia who are at low risk of requiring treatment, according to researchers.
Global Burden of Chronic Lymphocytic Leukemia Up From 1990 to 2019
The global burden of CLL increased from 40,537 cases in 1990 to 103,467 in 2019.
T-Cell Responses to COVID-19 Vaccines May Benefit Anti-CD20-Treated Lymphoma Patients
Despite an inferior rate of seroconversion, lymphoma patients treated with anti-CD20 therapy did mount T-cell responses.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL
Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.
Acalabrutinib Effective for Relapsed/Refractory CLL at 3 Years
The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.
Black Patients Less Likely to Receive Novel Agents as First-Line CLL Therapy
Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.
Lymphadenopathy in CLL Patients Predicts Richter’s Syndrome Risk After Ibrutinib
The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.
Ibrutinib Plus Venetoclax Produces Superior uMRD Responses in CLL
Researchers presented updated findings from the GLOW trial.
Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion
Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia News
Loading... 
Loading...